Tarsus Pharmaceuticals, Inc. TARS Indefinite-Lived Research and Development Assets
Indefinite-Lived Research and Development Assets at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s indefinite-lived research and development assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s indefinite-lived research and development assets?
- Tarsus Pharmaceuticals, Inc. (TARS) reported indefinite-lived research and development assets of $7.96M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s indefinite-lived research and development assets changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s indefinite-lived research and development assets decreased by 63.4% year-over-year, from $21.73M to $7.96M.
- What does indefinite-lived research and development assets mean?
- This represents the value of acquired in-process research and development projects that have not yet reached commercial viability. These assets are not amortized because their useful life is indeterminate until the project is either successfully completed or abandoned. This metric is vital for valuing the pipeline of a biopharmaceutical company and assessing the potential for future product launches.